CheckMate 8HW
01 Jul 2019
Trial Summary
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
Acronym:
CA209-8HW
ACTRN/NCT /ethics:
NCT04008030
Scientific title:
A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Sponsor / Cooperative group:
Bristol-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Bowel |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18+ years |
| Sex | All |
| Tumour Stream | Colorectal cancer |
| Cancer Stage | Locally Recurrent or Locally Advanced, Matastatic or Widespread |
| Anticipated Start Date | 2019-07-29 |
| Anticipated End Date | 2025-07-05 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |